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Niemann-Pick type C (NPC) disease is a neurovisceral atypical lipid storage disorder involving the accumulation of cholesterol
and other lipids in the late endocytic pathway. The pathogenic mechanism that links the accumulation of intracellular cholesterol
with cell death in NPC disease in both the CNS and the liver is currently unknown. Oxidative stress has been observed in the
livers and brains of NPC mice and in diﬀerent NPC cellular models. Moreover, there is evidence of an elevation of oxidative
stress markers in the serumof NPC patients. Recent evidence strongly suggests that mitochondrial dysfunction plays an important
role in NPC pathogenesis and that mitochondria could be a signiﬁcant source of oxidative stress in this disease. In this context,
the accumulation of vitamin E in the late endosomal/lysosomal compartments in NPC could lead to a potential decrease of its
bioavailability and could be another possible cause of oxidative damage. Another possible source of reactive species in NPC is
the diminished activity of diﬀerent antioxidant enzymes. Moreover, because NPC is mainly caused by the accumulation of free
cholesterol, oxidized cholesterol derivatives produced by oxidative stress may contribute to the pathogenesis of the disease.
1.Introduction
Niemann-Pick type C disease (NPC) is a neurovisceral
atypical lipid storage disorder that is mainly characterized
by unesteriﬁed cholesterol accumulation in late endosomal/
lysosomal (LE/Lys) compartments [1]. Several other kinds
of lipids, such as lactosylceramide, glucosylceramide and
GM2 and GM3 gangliosides, also accumulate in these com-
partments [2–5]. NPC is a fatal autosomal recessive disease
that is caused by mutations in the Npc1 or Npc2 genes
[6]. The Npc1 gene encodes a 1278-amino-acid lysosomal
transmembrane protein with 13 transmembrane domains
that have homology to the sterol-sensing domains (SSDs)
of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase,
SREBP cleavage-activating protein (SCAP), and Patched
[7, 8]. NPC1 protein localizes to the Rab7-positive and
mannose-6-P-receptor-negative late endosomal compart-
ment [9–11]. The Npc2 gene encodes a soluble lysosomal
protein that binds cholesterol [12] with a 1:1 stoichiometry
and submicromolar aﬃnity [13, 14]. Both proteins are
involved in cholesterol traﬃcking from lysosomes. The
current model for NPC1- and NPC2-mediated cholesterol
eﬄux is as follows: after lysosomal hydrolysis of LDL-
cholesteryl esters, cholesterol binds NPC2, which transfers
it to NPC1 [15]; subsequently, NPC1 mediates the exit of
cholesterol from lysosomes [16]. Mutations in the Npc1
gene account for approximately 95% of NPC cases, whereas
mutations in the Npc2 gene explain the remaining 5% [17].
The disease is often diagnosed in early childhood, with
patients typically displaying cerebellar ataxia, speaking and
swallowing diﬃculty, and progressive dementia [1, 17].
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supranuclear ophthalmoplegia, and its other prominent
neurologic features include cataplexy, dysarthria, dysphagia,
dystonia, and seizures [18, 19]. These symptoms are asso-
ciated with damage to the central nervous system (CNS),
especially in the cerebellum, where extensive and progressive
neuronal death is observed [20].
Although neuronal damage is a major feature of NPC,
most patients present considerable damage in the liver [2].
Indeed, NPC disease is recognized as a relatively common
cause of liver disease in early life [21]. Approximately half
of NPC patients suﬀer from liver disease, and NPC may be
the most common metabolic disorder that is responsible for
neonatal cholestasis [17].
The pathogenic mechanism linking the accumulation of
intracellular cholesterol with cell death in NPC disease is
currently unknown. However, increasing evidence indicating
the presence of oxidative damage in NPC neurons and data
connecting oxidative damage with ﬁbrosis and apoptosis in
the liver support the possibility that oxidative damage may
induce these pathways in NPC disease. The question that
remains unsolved is how oxidative damage is induced.
2.CellDeathandOxidativeDamageinNPC
The CNS is especially sensitive to oxidative stress damage
[22]. This sensitivity can be explained by several features of
the CNS: the high concentration of polyunsaturated fatty
acids that are susceptible to lipid peroxidation, the relatively
large amounts of oxygen consumed for energy production,
and the fewer antioxidant defenses available to the CNS
compared with other organs. In this sense, neurons are
particularly vulnerable to oxidative stress because they have
low levels of reduced glutathione (GSH) [23]. Oxidative
stress has been observed in diﬀerent NPC cellular models
[24]a sw e l la si nt h eb r a i n so fN P Cm i c e[ 25]; however,
the functional relevance of oxidative stress to the disease
process has not yet been established. In this context, we
have reported increased levels of nitrotyrosinilated (N-Tyr)
proteinsinthecerebellaofNPCmicebywesternblotanalysis
and an accumulation of N-Tyr-positive cells by immunoﬂu-
orescence [26]. Furthermore, Smith et al. detected positive
staining for N-Tyr in the thalami of NPC mice [25]. We have
alsofoundthat,inaneuronalmodelofthedisease,treatment
with an antioxidant compound diminished c-Abl kinase
activation and prevented cellular death and apoptosis [26].
This observation is particularly relevant because oxidative
stress is a potent activator of the c-Abl/p73 proapoptotic
pathway [27]. In fact, c-Abl/p73 activation kinetics correlate
with the kinetics of the appearance of oxidative-stress
markers in rat hippocampal neurons exposed to U18666A
(U18), an inducer of cholesterol accumulation in lysosomes
and a drug that has been widely used to induce the NPC
phenotype in diﬀerent cell types [28–30]. Highlighting the
roleofoxidativestressinNPC,wehaveshownthattreatment
with the antioxidant N-Acetyl Cysteine (NAC) prevented
c-Abl/p73 activation and apoptosis in NPC-like neurons,
suggestingthatoxidativestressisthemainupstreamstimulus
activating the c-Abl/p73 pathway in NPC neurons [26].
Livers of NPC mouse models present apoptosis, inﬂam-
mation, and ﬁbrosis. There is also functional damage, as
evidenced by the large increases in the levels of liver disease
markers such as plasmatic alanine and aspartate aminotrans-
ferases in NPC mice [31–33]. In support of the participation
of oxidative stress in NPC mouse livers, we have recently
found an increase in oxidative stress markers, such as protein
carbonyls and oxidative-stress related genes, and a decrease
in protective species, such as reduced glutathione [34].
Moreover, NPC patients present decreased antioxidant
capacity (expressed as Trolox equivalents) and reduced
Coenzyme Q10 in serum, which indicates a decrease in
antioxidant defenses [35]. In addition, an increase in choles-
terol oxidation products was detected in the plasma of NPC
patients [36]. Additionally, microarray studies have shown
that human NPC ﬁbroblasts exhibit an activation of the
apoptotic cascade and induction of genes related to oxidative
stress [37, 38]. Oxidative damage is present in animal and
cellular NPC models and in NPC patients; therefore, it may
have a relevant role in the pathogenesis and progression of
the disease.
3. Increasein MitochondrialCholesterol
andDysfunctioninNPC Disease
One possible element associated with oxidative damage in
NPC tissues could be mitochondrial dysfunction. In fact,
mitochondrial dysfunction appears to be a key element in
many neurodegenerative diseases and pathologies associated
with liver and cardiac damage as a signiﬁcant source of
oxidative stress [39–44].
However, the role of mitochondrial dysfunction in the
NPC disease phenotype remains undeﬁned. Recent studies
suggest that mitochondrial dysfunction and subsequent ATP
deﬁciency may be responsible for the neuronal impairment
in NPC disease [45]. These studies have demonstrated that
NPC mouse brains contained smaller and more rounded
mitochondria, with translucent matrices and irregular cis-
ternae. Moreover, the levels of ATP in the brain, muscle,
and livers of NPC mice are signiﬁcantly decreased compared
with those in WT mice [45]. Interestingly, several groups
have shown that the mitochondria of NPC neurons and
hepatocytes have a higher cholesterol content [45–48], and
increased cholesterol has also been shown in the mito-
chondria of HeLa cells treated with U18 [49]. These data
should be interpreted with caution, as it is diﬃcult to obtain
pure mitochondria uncontaminated by lysosomes because
of the interaction between these organelles as a result of
the increased autophagy in NPC cells [50, 51]. However,
treatment with the cholesterol chelator cyclodextrin restores
ATP synthesis and mitochondrial function [45], supporting
the idea that the increase in mitochondrial cholesterol causes
dysfunction per se. Therefore, a potential hypothesis is
that the increase in mitochondrial cholesterol content and
dysfunction may contribute to this damage (Figure 1).
Mitochondrial glutathione (mGSH) is the main line of
defense against the reactive oxygen species (ROS) generated
physiologically through the activity of the electron transportOxidative Medicine and Cellular Longevity 3
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Figure 1: Oxidative stress as a pathogenic mechanism in Niemann-Pick C disease. NPC disease arises from deﬁciencies in one of two
lysosomal proteins, NPC1 and NPC2, which are involved in the proper export of free cholesterol (CH) from lysosomes to diﬀerent
cellular compartments. Therefore, in NPC disease, free cholesterol accumulates inside the lysosomes and intracellular cholesterol transport
is impaired. Remarkably, vitamin E also accumulates inside the lysosomes, possibly diminishing its bioavailability and decreasing the
antioxidant capacity of the cell. Additionally, mitochondrial cholesterol is also increased, leading to a decrease in mGSH levels and
diminishing mitochondria antioxidant capacity. In this scenario, there is an increase in mitochondrial ROS production and a decrease in
ATP production. These two phenomena are well-known features of mitochondrial dysfunction. Furthermore, decreases of catalase activity
and increases in ROS production inside the peroxisomes have been reported. In summary, in NPC disease, alterations in several diﬀerent
organelles, including lysosomes, mitocondria, and peroxisomes, along with disturbances in copper (Cu) transport, trigger oxidative stress
damage, activating proapoptotic pathways and proapoptotic gene expression and inducing apoptotic cell death. Symbols: green up-arrows
indicateincreaseoractivation;reddown-arrowsindicatedecreaseorinhibition;boldblackarrowsrepresentmultisteppathways;angledblue
arrows indicate gene transcription activation.
chain in the mitochondria and is therefore a key player
in the maintenance of the appropriate mitochondrial redox
environment, preventing mitochondrial dysfunction, and
cell death. We have detected reduced GSH content in
the livers of NPC mice [34], and Mar´ ı et al. reported a
speciﬁc decrease of mGSH in NPC hepatocytes without
changes in cytosolic GSH [46]. Interestingly, the increase
in mitochondrial cholesterol seems to have a direct eﬀect
on the transport of GSH to the mitochondria, because the
activity of its transporter depends on membrane ﬂuidity
[52, 53]. A decrease of membrane ﬂuidity in mitochondria
or an increased cholesterol:phospholipid molar ratio, as
is observed in rat liver mitochondria after chronic alcohol
intake, results in an impairment of mGSH transport through
the 2-oxoglutarate carrier and, therefore, in a decrease
in mGSH levels [54]. Supporting a connection between
mitochondrialcholesterolcontentandreducedmGSHlevels,
evidence suggests that the hepatocytes of ob/ob mice or rats
fed high-cholesterol diets have reduced mGSH levels and
increased mitochondrial cholesterol content. Furthermore,
hepatocytes from these mice and those obtained from NPC
mice have decreased GSH content and increased sensitivity
to TNF-α cell death signaling [46].
In summary, regarding the role of mitochondrial dys-
functioninNPCdisease,ithasbeenobservedinNPCmodels
that important mitochondrial characteristics such as ATP
synthesis, mitochondrial morphology, and the input of GSH
to the mitochondrial matrix are altered. These alterations are
correlated with increased mitochondrial cholesterol content
and together result in a reduction in energy production,4 Oxidative Medicine and Cellular Longevity
increased ROS production, and increased energy demand in
NPC cells.
4. PeroxisomesAlterationsin NPC Disease
Another relevant source of ROS are the peroxisomes [55].
In fact, peroxisomal catalase is one of the most important
antioxidant enzymes that regulate intracellular H2O2 levels.
Interestingly, diﬀerent studies have shown early alterations
of several peroxisomal enzymatic activities, such as catalase,
and β-oxidation enzymes in the livers and cerebella of NPC
mice (Figure 1)[ 56]. There is also one clinical case report
of defective peroxisomal β-oxidation in an 18-month-old
NPCpatient[57].Moreover,treatmentofNPCmicewiththe
peroxisomal inducers perﬂuorooctanoic acid or cloﬁbrate
rescued peroxisomal and lysosomal enzyme activities and
decreased cholesterol content [58]. Furthermore, several
groups have demonstrated that the activity and protein levels
ofcatalaseareregulatedinabiphasicfashionbyc-Ablkinase.
At low H2O2 levels, catalase interacts with c-Abl, which
stabilizes catalase by phosphorylating it at Tyr residues.
Meanwhile, at high H2O2 levels or after sustained proapop-
totic stimulus, c-Abl translocates to the nucleus to perform
its proapoptotic function without phosphorylating catalase,
which in turn is degraded [59–61]. Although it is still
unknown where the interaction between intraperoxisomal
catalase and c-Abl (which is located in cytosol, endoplasmic
reticulum and the nucleus) occurs, this regulation has been
demonstrated in several cell types, including ﬁbroblasts
and 293 cells [61]. As was mentioned above, we have
demonstrated that in NPC neurons, the c-Abl kinase is
activated and induces apoptosis [26, 62]. These antecedents
suggest that reduced catalase activity in NPC cells could
be related to alterations in c-Abl regulation mechanisms,
contributingtotheoxidative damageobservedinthedisease.
5.IntracellularAccumulation of
VitaminEinNPCDisease
Intracellular accumulation of vitamin E and decreased bi-
oavailability of this antioxidant has emerged as one of the
possible causes of oxidative damage in NPC. Vitamin E,
and in particular α-tocopherol, its most important biological
derivative, is one of the most relevant antioxidant defense
molecules in addition to GSH. Both react directly with free
radicals to form inactive, nonradical products [63–67].
Data from the literature and results from our lab show
increased levels of α-tocopherol in the cerebella and a
tendency to increase in the livers of NPC mice, and α-
tocopherol accumulation was observed in several NPC in
vitro models in a ﬁlipin-positive compartment (Figure 1)
[68, 69]. Interestingly, one of the most damaged regions
in NPC disease, the cerebellum, contains high levels of
vitamin E [70]. Furthermore, mutations in the gene coding
for the α-tocopherol transporter protein (α-Ttp) result
in a neurologic syndrome of spinocerebellar ataxia called
Ataxia with Vitamin E Deﬁciency or AVED. This condition
is characterized by progressive ataxia, dysarthria, sensory
loss, and severe damage of Purkinje cells [70, 71], sharing
some symptoms with NPC patients. In addition, vitamin E
supplementation has been demonstrated to protect against
age-related deﬁcits in Purkinje cell-β adrenergic receptor
function and ethanol-induced Purkinje cell loss in rats [72,
73]. Moreover, interestingly, NPC1-like 1 (NPC1L1), which
is the closest NPC1 homologue, mediates α-tocopherol
transport in rat intestines [74].
Collectively, these data suggest that vitamin E transport
through lysosomes could be mediated by NPC proteins and
that it might therefore be altered in NPC cells. Because
vitamin E is essential for health and increasing evidence
suggest that antioxidants have a protective role in oxidative
damage-associateddiseases,studiesontheaccumulationand
bioavailability of vitamin E in NPC cells are relevant for
understanding the pathophysiology of this disease and the
possible beneﬁts of vitamin E therapy.
Interestingly, in addition to its antioxidant properties,
α-tocopherol also induces signaling in cells [75]. It has
been shown that α-tocopherol activates phosphatase 2A
(PP2A), causing dephosphorylation and diminishing PKC
alpha activity in various types of cells [75]. In addition, α-
tocopherolinhibitsTNF-α-inducedERK1/2andp38MAPKs
activation [76]. These results suggest an anti-inﬂammatory
action of α-tocopherol in addition to its antioxidant proper-
ties.
Our hypothesis is that vitamin E is trapped in LE/Lys and
that it has a decreased bioavailability in NPC cells (Figure 1).
However, we cannot disregard a diﬀerent scenario in which
the excess vitamin E compounds acting as prooxidants
in NPC cells. In fact, α-TOH can play diverse roles in
lipoprotein oxidation, displaying neutral, anti-, or, indeed,
prooxidant activities under various conditions [77]. For
example, in the presence of determinant Cu2+/LDL ratios,
α-TOH acts as a mediator of LDL lipid peroxidation [78].
Therefore, an alternative hypothesis is that the lysosomal
buildup of vitamin E found in NPC cells could actively
contributetothepathology,actingasapro-oxidantmolecule
and increasing the levels of toxic cholesterol oxidation
products.
It is therefore important to mention that a previous
in vivo study [79] showed that treatment with vitamin E
exerts a small but signiﬁcant beneﬁcial eﬀect on locomotor
performance in NPC mice. It may be assumed that the
eﬀects of this treatment were small because part of the
vitaminEwastrappedinthelysosomesandwasnotavailable
as cell antioxidants, making it less likely that the small
protective eﬀect is due to its behavior as a pro-oxidant
molecule. Furthermore, another study with vitamin C failed
to obtain a signiﬁcant beneﬁt in NPC mice [25]; this failure
might be related to the lack of neuroprotective properties of
vitamin C in neurodegenerative diseases in which oxidative
stress plays a key role and vitamin E serves as a neuro-
protectant [80]. On the other hand, there is evidence for
other potential NPC treatments that can be neuroprotective.
Early treatment with the neurosteroid allopregnanolone
also improved neurological symptoms and survival in NPC
mice by correcting the neurosteroidogenic abnormalities
[81]. Interestingly, allopregnanolone was demonstrated toOxidative Medicine and Cellular Longevity 5
work as a potent antioxidant in in vitro NPC models [82].
Treating NPC mice in vivo with curcumin, a potent activator
of the antioxidant Nrf2 pathway [83], also improves the
neurological symptoms and survival of NPC mice [5]. All
these studies indicate a relevant role for oxidative stress in
NPC-related neurodegeneration.
6. Glycosphingolipid Accumulation
inNPC Disease
It is important to note that in NPC disease, there is not only
cholesterol accumulation in the LE/Lys compartment but
also an increased accumulation of other kinds of lipids. The
improvement observed in patients treated with miglustat
(Zavesca; Actelion Pharmaceuticals Ltd., Allschwil, Switzer-
land) can be attributed to its capacity to decrease the levels of
glycosphingolipids. The accumulation of glycosphingolipids
leads to defective intracellular calcium signaling, as has been
demonstrated in several gangliosidoses [84]. Defective intra-
cellular calcium could be detrimental for the cell because
calcium plays vital roles in regulating a variety of cellular
events, with impaired calcium homeostasis leading to endo-
plasmicreticulum(ER)stress,oxidativestress,andcelldeath.
Moreover, Platt’s group has demonstrated that sphingosine
storage,anearlyeventinNPCLE/Lys,causesauniquedefect,
inhibiting the ﬁlling of the LE/Lys calcium store [5]. Indeed,
treatment of NPC1 CHO cells with thapsigargin elevated
cytosolic calcium and corrected the NPC cellular phenotype,
reducing glycosphingolipid and cholesterol accumulation.
Additionally, the chelation of LE/Lys calcium content in
healthy cells induces a set of cellular phenotypes identical
to NPC, including defective endocytic transport and the
subsequent storage of cholesterol, glycosphingolipids, and
sphingomyelin [5, 85].
The depletion of glycosphingolipids by miglustat treat-
mentreducespathologicallipidstorage,improvesendosomal
uptake, and normalizes lipid traﬃcking in peripheral blood
Bl y m p h o c y t e s[ 86]; however, the incomplete success of
miglustat treatment in patients may be because it addresses
only one aspect of the pathological cascade of NPC disease.
Fu and colleagues [87] showed that miglustat therapy does
not signiﬁcantly improve oxidative stress in NPC patients.
This result suggests that oxidative stress is an independent
pathological process and that combination therapies that
include an antioxidant may have an additional beneﬁt in
NPC patients.
7. Other Sources of ReactiveSpeciesin
OxidativeDamage in NPC
Another possible source of reactive species in NPC is the
diminished activity of diﬀerent antioxidant enzymes. For
example, catalase is one of the most important antioxidant
enzymes participating in the regulation of intracellular
H2O2, and, as mentioned previously, its levels are decreased
in the livers and brains of NPC mice [56]. In addition,
another antioxidant enzyme located in the cytosol and mito-
chondria, glutathione peroxidase 1, or GPx1, is regulated
in the same way by the proapoptotic kinase c-Abl [61, 88],
which is activated in NPC neurons. The activity of GPx1
is thought to be relevant to antioxidant defenses at the
neuronal level, and GPx1−/− mice showed greater apoptosis-
related sensitivity and damage in the brain when faced
with extreme oxidative damage, such as that produced by
ischemia-reperfusion [89].
Oxygen species are not the only inducers of oxidative
damage to biomolecules. There is evidence for nitric-oxide-
(NO-) mediated damage in NPC. Peroxynitrite binds a
nitro group to tyrosines, inducing protein nitrotyrosination,
whichnegatesthephysiologicalfunctionoftheproteins[90].
Interestingly, NO levels are elevated in neural stem cells
(NSCs) from NPC mice and NSC self-renewal is decreased
[91], suggesting that oxidative stress damage could be rele-
vant in NPC neurodegeneration, even at the early stages of
development [92]. Moreover, microarray analyses of human
NPC ﬁbroblasts have revealed an increase in NO synthase
mRNA expression [37] and an increase in N-Tyr staining has
been reported in ﬁbroblasts [93].
Considering other additional sources for oxidative stress,
we previously reported copper accumulation (Figure 1)i n
the liver [34] and plasma, along with a decrease of copper
excretion into the bile of Npc1−/− (NPC) mice (unpublished
results). These data are in agreement with previous reports
of copper increase and ceruloplasmin alterations in a cellular
NPC model [94, 95]. Copper is an important micronutrient
that plays an essential role in human physiology [96].
Increases in copper, iron, or zinc levels have been described
as risk factors for oxidative stress damage in neurodegen-
erative pathologies, such as amyotrophic lateral sclerosis,
Alzheimer’s Disease, and Parkinson’s Disease [97]. Fur-
thermore, mutations in copper-binding proteins have been
linked to those devastating disorders [98] and to Wilson
disease and Menkes disease [99, 100]. Therefore, appropriate
levels of copper are essential to avoid cellular damage by
oxidative stress due to the rapid oxidation of copper, which
causes damage to biomolecules and generates ROS, leading
to cell death [101].Theli v erpla ysamajorr oleinthisdelicat e
maintenance of copper homeostasis, because most of the
newly absorbed copper enters the liver after absorption from
dietary sources in the small intestine. Additionally, the liver
regulates the distribution of copper through its release into
the plasma when bound to ceruloplasmin or by its excretion
via bile [102]. Moreover, the expression of genes involved in
metalhomeostasisandtransport,includingiron,copper,and
zinc, was reported to be altered in NPC ﬁbroblast microarray
studies [37, 38], suggesting alterations in metal levels in NPC
disease.
As NPC is mainly caused by the accumulation of free
cholesterol,itcanbeexpectedthatoxidizedcholesterolderiv-
ativesareproducedinthepresenceofoxidativestress.Infact,
an increase in cellular cholesterol oxidation products, suchas
7-ketocholesterol (7-KC), 7β-hydroxycholesterol (7β-HC),
and cholestane-3β,5α,6β-triol (3β,5α,6β-triol), has been
described in NPC mouse tissues, plasma, and macrophages
[36, 103, 104]. They are produced by the nonenzymatic
oxidation of cholesterol with ROS and several of them have
been reported to be cytotoxic in vitro [105]. Although the6 Oxidative Medicine and Cellular Longevity
mechanism of oxysterol production in NPC is unclear, and
most of the cholesterol should accumulate in lysosomes, the
elevation of oxysterol levels in the disease has been consist-
ently reproduced in mice and humans, and they have been
proposed as biomarkers for NPC [36]. Moreover, 7-KC sig-
naling has been shown to be modulated by vitamin E. It has
been demonstrated that α-tocopherol impedes the cellular
signaling of 7-KC, inhibiting its incorporation in lipid rafts
[106]. As such, if there is less bioavailability of vitamin E
in NPC cells, the proapoptotic eﬀect of 7-KC, through its
inhibition of the phosphatidylinositol 3-kinase/Akt survival
pathway [107], could be further increased.
Remarkably, a study by Porter et al. [36] showed that
cholesterolo xidationproductlevelscorrelatedwiththeageof
disease onset and disease severity in NPC mice and humans.
Thus, cholesterol oxidation products have been proposed as
blood-based biochemical markers for NPC disease that may
prove informative for the diagnosis and treatment of this
disorder and as outcome measures to monitor the response
to therapy. These results suggest that oxidative damage is an
important element in the pathology of NPC disease.
8. PutativeTreatments for NPC Disease
Unfortunately, there is no fully eﬀective treatment for this
devastating and fatal disorder to date, only supportive
measures for the relief of speciﬁc manifestations of the
disease. Interventions to slow disease progression are the
most promising therapies. Several experimental disease-
speciﬁc therapies based on the molecular pathology of NPC
have been tested in cell culture and animal models, including
neurosteroids, cholesterol-binding agents (e.g., cyclodex-
trin), and molecules with antioxidant properties, such as
curcumin and miglustat [108].
Among the cholesterol-binding agents, cyclodextrin
seems to be promising [109], although data suggesting
limitedornoblood-brainbarrierpenetrationofcyclodextrin
following systemic administration have to be considered
[110]. Treatment of NPC mice with cyclodextrin reduces the
neurodegeneration and markedly extends the life span of
NPC mice, suggesting a potential therapeutic approach for
the treatment of individuals with NPC disease [111]. The
mechanisms by which cyclodextrin mediates these beneﬁcial
eﬀects are still unknown. The evidence shows that a single
injection of cyclodextrin at p7 in NPC mice caused a
marked increase in cholesteryl esters and the suppression of
cholesterol synthesis in many organs, as well as changes in
the expression of genes responsive to cholesterol levels [112],
suggesting that cyclodextrin acutely reverses the lysosomal
transportdefectobservedinNPCdisease.However,although
cyclodextrin has promising eﬀects in the brain and liver, it
has little or no eﬀect at all on lung dysfunction, another
important issue in NPC pathology [113]. Nonetheless, the
positive data on cyclodextrin reported in model animals
have encouraged its application as a potential treatment in
NPC patients. In fact, last year, the European Medicines
Agency (EMA) granted Hydroxypropyl-beta-cyclodextrin
(HPbCD) orphan drug status and designated the compound
as a potential treatment for NPC disease. In addition, the
National Institutes of Health (NIH) in collaboration with
the Therapeutics for Rare and Neglected Diseases Program
(TRND) announced that they are developing a clinical trial
utilizing cyclodextrin for NPC patients. This clinical trial is
in the planning phase and is not yet oﬃcially approved by
the FDA.
Regarding the use of antioxidant molecules, it has re-
cently been reported that NPC patients showed signiﬁcant
decreasesinthefractionsofreducedcoenzymeQ10(CoQ10)
[87]. This decrease in CoQ10 levels can cause changes
similar to those reported in patients with deﬁciencies in
CoQ10. CoQ10 deﬁciency is a rare human genetic condition
that has been associated with a variety of clinical pheno-
types: decreased activities of complex II + III, complex III
and complex IV, reduced expression of the mitochondrial
proteins involved in oxidative phosphorylation, decreased
mitochondrial membrane potential, increased ROS activa-
tion of mitochondrial permeability transition (MPT), and
reduced growth rates [114]. In ﬁbroblasts from patients with
CoQ deﬁciency, these abnormalities were partially restored
by CoQ supplementation [114]. However, supplementation
with CoQ10 does not correct the abnormal fraction of
reduced CoQ10 found in NPC patients [87]. Although the
treatment did not restore the levels of reduced CoQ10 in
NPC patients, the authors did not analyze the eﬀect of the
treatment on mitochondrial function and ROS production.
Currently, there is an active clinical protocol to test the
safety and eﬃcacy of the antioxidant NAC in NPC patients at
the National Institute of Health Clinical Center in the U.S.A.
(http://clinicaltrials.gov/ct2/show/NCT00975689). NAC is a
powerful antioxidant that acts by increasing cellular glu-
tathione levels [115–117]. The advantage of using NAC lies
in the fact that it has been approved by the FDA to treat
acetaminophen poisoning or to reduce mucous stickiness in
patients with cystic ﬁbrosis. Plasma oxysterol analysis will be
used as a biomarker in the treatment, because Ory’s group
has previously demonstrated an increase of oxysterols in the
plasma of NPC mice [103]. Interestingly, NAC treatment
shows beneﬁcial eﬀects not only in neurodegenerative dis-
eases such as Alzheimer’s but also in myocardial dysfunction
[116]. In addition, we have reported a decrease of foamy
cells on the livers of 7-week-old NPC mice after 2 weeks of
treatmentwithNAC [34], and we also have shown a decrease
in apoptosis in U18-treated neurons incubated with NAC
[26]. Although the acute use of NAC has demonstrated clear
beneﬁcial eﬀects [86], its chronic use for the treatment of
diseases associated with oxidative damage is controversial
[118], mainly because, to date, there have not been positive
results reported in this clinical trial, so it is not clear if this
treatment could be eﬀective. A possible explanation for this
lack of eﬀectiveness is that the antioxidant eﬀect of NAC
results from its ability to restore the cytosolic levels of GSH,
which is transported to mitochondria, where it exerts its
detoxifying function. The mitochondrial transport of GSH
is highly sensitive to membrane dynamics, and this transport
is delayed in hepatocytes from NPC mice and is correlated
with mitochondrial GSH (mGSH) depletion [46]. Therefore,
NAC therapy would not be eﬀective in NPC disease, becauseOxidative Medicine and Cellular Longevity 7
although the levels of cytosolic GSH are increased, GSH
transport into mitochondria remains defective.
Following this line of evidence, it has recently been
shown that a curcumin derivative, J147, has the ability to
prevent memory deﬁcits in AD transgenic mice, and this
eﬀect is correlated with the reduction of markers for oxida-
tive stress damage and inﬂammation [119]. Furthermore, it
has previously been reported that curcumin treatment can
normalize cytosolic calcium levels, prolonging the survival
of NPC mice [5]. However, this explanation might not be the
only one for the curcumin protective eﬀect, as it is also an
antioxidant molecule.
Another putative drug that may be useful in ameliorating
NPC symptomatology is imatinib, a speciﬁc c-Abl kinase
inhibitor. Imatinib treatment increased the quality of life of
NPC mice by delaying body weight loss and neurological
symptoms, decreasing cerebellar apoptosis and inﬂamma-
tion, and increasing Purkinje cell survival. However, the
inhibition of c-Abl with imatinib did not aﬀect oxidative
stress levels, suggesting that c-Abl/p73 activation in NPC
is downstream of oxidative stress. Nonetheless, inhibition
of the c-Abl/p73 module is still an interesting therapeutic
target in NPC and perhaps in other neurological disorders
as well [62]. Interestingly, imatinib (Gleevec, STI571) is a
U.S. Food and Drug Administration-approved drug used in
patients with chronic myelogenous leukemia, in which the
therapeutic target is the aberrant oncogenic fusion protein
Bcr-Abl [120, 121].
Finally, it seems that the path to an eﬀective therapy
for NPC disease could be a multidrug approach that
combines antioxidant and anti-inﬂammatory compounds
with other drugs that improve lipid metabolism. In this
sense, it is important to note that the ﬁrst and only
approved therapy for patients with NPC, miglustat [122–
124], is a reversible inhibitor of glucosylceramide synthase,
which catalyzes the ﬁrst committed step of glycosphingolipid
synthesis. Miglustat is currently approved in the European
Union (EU), USA, Canada, Brazil, Australia, Turkey, Israel,
Switzerland, South Korea, and New Zealand for the treat-
ment of patients with Gaucher disease. In January 2009,
the EU Commission extended miglustat’s indication to
include the treatment of progressive neurological manifesta-
tions in adult pediatric patients with NPC. This extension
was followed by authorization in Brazil and South Korea
[108, 125].
9. Concluding Remarks
NPC disease is a fatal disorder without an eﬃcient treatment
available. Several approaches have attempted to at least delay
the disease progress. A better understanding of the mech-
anisms involved in the pathogenesis of NPC is necessary
to design appropriate and eﬀective therapeutic approaches.
Increasing evidence indicates that oxidative stress damage
hasanimportantroleinthepathophysiologyofNPCdisease.
Therefore, drugs that can decrease or ameliorate oxidative
stress damage and apoptosis must be used in combination
with other pharmacological strategies that restore the proper
metabolism and transport of lipids, especially cholesterol, in
NPC patients.
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